Welcome!

Agile Computing Authors: Liz McMillan, Kevin Jackson, LeanTaaS Blog, Yeshim Deniz, Elizabeth White

News Feed Item

Express Scripts Reports Third Quarter Results

Raises Full Year Earnings Guidance

ST. LOUIS, Nov. 5, 2012 /PRNewswire/ -- Express Scripts (Nasdaq: ESRX) announced 2012 third quarter net income of $391.4 million, or $0.47 per diluted share.  Adjusted earnings per share, as detailed in Table 4 were $1.02 per diluted share for the third quarter.

"Our solid third quarter results demonstrate our continued success as a combined organization," stated George Paz, chairman and chief executive officer.  "Integration continues on track and together we are building on our legacy of advancing healthcare through innovation and an unwavering alignment with our clients."

Third Quarter 2012 Review (Data reflected on an adjusted basis. See Tables 2 and 3)

All key metrics compared to 2011 were affected by the inclusion of Medco results beginning in the second quarter of 2012.  Gross profit margin and EBITDA per adjusted claim increases over last year are mainly attributed to improved operating performance, including increased generic utilization.

  • Adjusted claims of 398.9 million, up 116% from third quarter 2011  
  • Gross profit of $2.2 billion, up 153% from third quarter 2011
  • Gross profit margin of 8.1% up from 7.5% in third quarter 2011
  • EBITDA of $1.6 billion, up 136% from third quarter 2011
  • EBITDA per adjusted claim of $4.06, up 9% from third quarter 2011
  • Year to date cash flow from operations of $2.0 billion, up 23% from third quarter 2011

2012 Guidance

Due to strong operating performance, increased generic utilization and the accelerated realization of synergies, the Company now expects to achieve adjusted earnings per share for 2012 in the range of $3.65 to $3.75.  Adjusted earnings per share excludes items as detailed in Table 5. 

Total adjusted claims are expected to be approximately 1.4 billion.  The guidance range assumes 2012 diluted weighted-average shares of 750 million.  Diluted weighted-average shares may differ due to, among other factors, the exercise of stock options and settlement of restricted stock units, and differences in the dilutive impact of awards granted under either of Express Scripts' or Medco's share-based compensation agreements.  The guidance range assumes a full year 2012 adjusted effective tax rate of approximately 39.6%.  Variations in assumed diluted weighted-average shares and tax rate may materially impact the guidance range.

The successful integration of Medco continues, with the Company meeting or exceeding its targets.

2013 Economic and Environmental Outlook

Express Scripts previously announced that it will provide 2013 guidance in conjunction with its fourth quarter results.  In addition to the expected claims loss from the UnitedHealthcare book of business throughout the year, the Company believes its 2013 outlook will also be influenced by the current weak business climate and the unemployment outlook.  These factors would likely result in significant in-group member attrition, continued low utilization rates and increased client demands and expectations.

Express Scripts expects to grow earnings per share and EBITDA in 2013.  However, given the factors discussed above, the Company views current consensus estimates for 2013 as overly aggressive.

"Despite near-term headwinds and a challenging macroeconomic environment, we remain confident we are well-positioned for continued growth", stated Paz.  "We have historically managed expenses rigorously while investing toward the future, focusing on innovation, service and optimal clinical outcomes, and will continue to do so, even when faced with challenges on other fronts."  

About Express Scripts

Express Scripts manages more than a billion prescriptions each year for tens of millions of people. On behalf of our clients — employers, health plans, unions and government health programs — we make the use of prescription drugs safer and more affordable. We innovate to enhance patient care, reduce pharmacy-related waste and increase therapy adherence. Building on a strong clinical foundation, we apply our understanding of the behavioral sciences — an approach we call Consumerology® — to make it easier for people to choose better health.

Headquartered in St. Louis, Express Scripts provides integrated pharmacy benefit management services, including network-pharmacy claims processing, home delivery, specialty benefit management, benefit-design consultation, drug-utilization review, formulary management, and medical and drug data analysis services. The company also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services.

For more information, visit www.Express-Scripts.com or follow @ExpressScripts on Twitter.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements, including, but not limited to, statements related to the Company's plans, objectives, expectations (financial and otherwise) or intentions. Actual results may differ significantly from those projected or suggested in any forward-looking statements.  Factors that may impact these forward-looking statements can be found in the Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's Form 10-Q filed with the SEC on or about November 5, 2012.  A copy of this form can be found at the Investor Relations section of Express Scripts' web site at http://www.express-scripts.com/corporate.

We do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

 EXPRESS SCRIPTS HOLDING COMPANY 

 Unaudited Consolidated Statement of Operations 










 Three Months Ended

September 30, 


 Nine Months Ended

September 30, 

(in millions, except per share data) 

2012


2011


2012


2011









Revenues(1)

$ 26,999.4


$ 11,571.0


$ 66,824.5


$ 34,026.9

Cost of revenues(1)

24,864.9


10,735.2


61,745.1


31,661.5

    Gross profit 

2,134.5


835.8


5,079.4


2,365.4

Selling, general and administrative

1,336.0


230.7


3,220.7


628.6

Operating income

798.5


605.1


1,858.7


1,736.8

Other (expense) income:








    Undistributed gain from joint venture 

5.1


-


9.4


-

    Interest income  

1.4


5.9


6.0


7.8

    Interest expense and other 

(155.9)


(94.3)


(463.1)


(184.3)


(149.4)


(88.4)


(447.7)


(176.5)

Income before income taxes

649.1


516.7


1,411.0


1,560.3

Provision for income taxes

257.7


192.0


602.2


574.9

Net income 

$      391.4


$      324.7


$      808.8


$      985.4









Weighted average number of common shares








 outstanding during the period: 








    Basic 

812.9


487.2


702.4


506.1

    Diluted 

829.6


490.8


718.9


510.3









Basic earnings per share

$        0.48


$        0.67


$        1.15


$        1.95









Diluted earnings per share

$        0.47


$        0.66


$        1.13


$        1.93









(1) Includes retail pharmacy co-payments of $3,348.9 million and $1,390.4 million for the three months ended September 30, 2012 and 2011, respectively and $8,364.6 million and $4,374.0 million for the nine months ended September 30, 2012 and 2011, respectively. 



 EXPRESS SCRIPTS HOLDING COMPANY 

 Unaudited Consolidated Balance Sheet 






 September 30,  


   December 31, 

 (in millions) 

2012


2011

 Assets 




 Current assets: 




 Cash and cash equivalents 

$          1,248.4


$       5,620.1

 Restricted cash and investments 

47.3


17.8

 Receivables, net 

5,720.3


1,915.7

 Inventories 

1,561.4


374.4

 Deferred taxes 

417.3


45.8

 Prepaid expenses and other current assets 

437.8


84.2

    Total current assets 

9,432.5


8,058.0

 Property and equipment, net 

1,710.2


416.2

 Goodwill 

29,367.5


5,485.7

 Other intangible assets, net 

16,735.9


1,620.9

 Other assets 

61.6


26.2

    Total assets 

$        57,307.7


$     15,607.0





 Liabilities and Stockholders' Equity 




 Current liabilities: 




 Claims and rebates payable 

$          6,710.0


$       2,874.1

 Accounts payable 

2,139.4


928.1

 Accrued expenses 

1,964.9


656.0

 Short-term loan payable 

40.0


-

 Current maturities of long-term debt 

938.6


999.9

    Total current liabilities 

11,792.9


5,458.1

 Long-term debt 

16,146.3


7,076.4

 Other liabilities 

6,623.6


598.8

    Total liabilities 

34,562.8


13,133.3





 Stockholders' Equity: 




 Preferred stock, 15.0 shares authorized, $0.01 par value per share;   



 and no shares issued and outstanding 

-


-

 Common stock, 2,985.0 shares authorized, $0.01 par value per share;  



 shares issued: 809.6 and 690.7, respectively; 




 shares outstanding: 809.6 and 484.6, respectively 

8.1


6.9

 Additional paid-in capital 

21,156.1


2,438.2

 Accumulated other comprehensive income 

16.6


17.0

 Retained earnings 

1,564.1


6,645.6


22,744.9


9,107.7





 Common stock in treasury at cost, zero and 206.1 shares, respectively 

-


(6,634.0)

    Total stockholders' equity 

22,744.9


2,473.7

    Total liabilities and stockholders' equity 

$        57,307.7


$     15,607.0









 EXPRESS SCRIPTS HOLDING COMPANY 

 Unaudited Consolidated Statement of Cash Flows 


 Nine Months Ended

September 30, 

 (in millions) 

2012


2011





 Cash flows from operating activities: 




 Net income  

$     808.8


$    985.4

 Adjustments to reconcile net income to net cash provided by operating activities: 




 Depreciation and amortization 

1,292.0


187.5

 Non-cash adjustments to net income 

37.8


152.9

 Deferred financing fees 

32.1


44.9

 Changes in operating assets and liabilities, net of effects of acquisition:  




 Accounts receivable 

382.6


(58.1)

 Claims and rebates payable 

(647.2)


44.4

 Other net changes in operating assets and liabilities 

143.3


302.9

 Net cash flows provided by operating activities 

2,049.4


1,659.9





 Cash flows from investing activities: 




 Acquisition of business, net of cash acquired 

(10,283.6)


-

 Purchases of property and equipment 

(106.0)


(98.1)

 Proceeds from sale of business 

31.5


-

 Other 

(16.2)


8.5

 Net cash used in investing activities 

(10,374.3)


(89.6)





 Cash flows from financing activities: 




 Proceeds from long-term debt, net of discounts 

7,458.9


1,494.0

 Repayment of long-term debt 

(2,710.6)


(0.1)

 Proceeds (repayment) of revolving credit line, net 

(1,000.0)


-

 Proceeds from accounts receivable financing facility 

600.0


-

 Repayment of accounts receivable financing facility 

(601.3)


-

 Excess tax benefit relating to employee stock compensation 

30.4


27.3

 Net proceeds from employee stock plans 

276.5


28.9

 Deferred financing fees 

(103.2)


(62.7)

 Treasury stock acquired 

-


(2,515.7)

 Net cash provided by (used in) financing activities 

3,950.7


(1,028.3)





 Effect of foreign currency translation adjustment 

2.5


(3.1)





 Net (decrease) increase in cash and cash equivalents 

(4,371.7)


538.9

 Cash and cash equivalents at beginning of period 

5,620.1


523.7

 Cash and cash equivalents at end of period 

$  1,248.4


$ 1,062.6









Table 1

Express Scripts Holding Company Unaudited Consolidated Selected Information

(in millions)










Three Months Ended

September 30,


Nine Months Ended

September 30,

Claims Volume

2012


2011


2012


2011

Network

282.9


147.2


721.5


444.0

Home delivery and specialty(1)

39.8


13.3


94.5


39.9

  Total claims

322.7


160.5


816.0


483.9









Total adjusted claims(2)

398.9


184.8


996.0


556.6









Depreciation and Amortization (D&A):








Revenue amortization(3)

$ 28.5


$ 28.5


$ 85.5


$ 85.5

Cost of revenues depreciation

39.4


9.6


76.5


31.2

Selling, general and administrative depreciation

47.9


13.1


121.7


40.3

Selling, general and administrative amortization

506.0


10.1


1,008.3


30.5

  Total D&A

$ 621.8


$ 61.3


$ 1,292.0


$ 187.5









Generic Fill Rate








Network

79.7%


75.3%


78.9%


75.2%

Home delivery

72.2%


63.0%


70.6%


62.5%

Overall

78.8%


74.1%


78.0%


74.0%









Note: See Appendix for footnotes.










Table 2

Calculation of Express Scripts Holding Company Adjusted Gross Profit and SG&A

(in millions)










Three Months Ended

September 30,


Nine Months Ended

September 30,


2012


2011


2012


2011

Gross profit, as reported

$ 2,134.5


$ 835.8


$ 5,079.4


$ 2,365.4

Amortization of legacy Express Scripts intangible assets (3)

28.5


28.5


85.5


85.5

Non-recurring transaction and integration costs (4)

21.8


-


33.7


-

Adjusted gross profit

$ 2,184.8


$ 864.3


$ 5,198.6


$ 2,450.9









Selling, general and administrative, as reported

$ 1,336.0


$ 230.7


$ 3,220.7


$ 628.6

Amortization of legacy Express Scripts intangible assets (3)

10.1


10.1


30.5


30.5

Amortization of Medco-related intangible assets (5)

495.9


-


977.8


-

Non-recurring transaction and integration costs (4)

179.1


20.3


586.1


20.3

Adjusted selling, general and administrative

$  650.9


$  200.3


$ 1,626.3


$  577.8









Note: See Appendix for footnotes.
















The Company is providing adjusted gross profit and selling, general and administrative expenses excluding the impact of non-recurring charges and amortization of intangible assets in order to compare the underlying financial performance to prior periods.

















Table 3

Express Scripts Holding Company EBITDA Reconciliation

(in millions, except per claim data)

 

The following is a reconciliation of net income to EBITDA(6). The Company believes net income is the most directly comparable measure calculated under U.S. GAAP.

 


Three Months Ended

September 30,


Nine Months Ended

September 30,



2012


2011


2012


2011


Net income, as reported

$    391.4


$  324.7


$   808.8


$    985.4


  Provision for income taxes

257.7


192.0


602.2


574.9


  Depreciation and amortization

621.8


61.3


1,292.0


187.5


  Interest expense, net

154.5


88.4


457.1


176.5


  Undistributed gain from joint venture

(5.1)


-


(9.4)


-


EBITDA, as reported

1,420.3


666.4


3,150.7


1,924.3


Non-recurring transaction and integration costs (4)

200.9


20.3


619.8


20.3


Adjusted EBITDA

$ 1,621.2


$ 686.7


$ 3,770.5


$ 1,944.6











Total adjusted claims

398.9


184.8


996.0


556.6











Adjusted EBITDA per adjusted claim

$      4.06


$   3.72


$      3.79


$      3.49











Note: See Appendix for footnotes.


















The Company is providing EBITDA excluding the impact of non-recurring charges in order to compare the underlying financial performance to prior periods.

 

Table 4

Calculation of Express Scripts Holding Company Adjusted EPS










Three Months Ended

September 30,


Nine Months Ended

September 30,


2012


2011


2012


2011


(per diluted share)

EPS, as reported

$ 0.47


$ 0.66


$ 1.13


$ 1.93









Non-recurring/transaction-related items:








Transaction and integration costs (4)

0.15


0.03


0.51


0.03

Medco acquisition pre-close financing costs (7)

-


0.05


0.07


0.05

Discrete tax items (8)

-


-


0.06


-









Amortization of:








Legacy Express Scripts intangible assets(3)

0.03


0.05


0.10


0.14

Medco-related intangible assets(5)

0.37


-


0.81


-









EPS, adjusted

$ 1.02


$ 0.79


$ 2.68


$ 2.15









Note: See Appendix for footnotes.
















The Company is providing diluted earnings per share excluding the impact of non-recurring / transaction-related items and amortization of intangible assets in order to compare the underlying financial performance to prior periods.

















Table 5

2012 Guidance Information


Estimated

Year Ended

December 31, 2012


(per diluted share)





Revised adjusted EPS guidance

$ 3.65

to

$ 3.75





GAAP items not included in guidance:








Amortization of legacy Express Scripts intangible assets

$0.12



Amortization of Medco-related intangible assets (9)

$1.19





Transaction and integration costs(10)

To be determined





The guidance range assumes 2012 diluted weighted-average shares of 750 million.  Diluted weighted-average shares may differ due to, among other factors, the exercise of stock options and settlement of restricted stock units, and differences in the dilutive impact of awards granted under either of Express Scripts' or Medco's share-based compensation agreements.  The guidance range assumes a full year 2012 adjusted effective tax rate of approximately 39.6%.  Variations in assumed diluted weighted-average shares and tax rate may materially impact the guidance range. 





 Note: See Appendix for footnotes.  












 Appendix 

 Footnotes 


(1)Includes home delivery, specialty and other including:  (a) drugs distributed through patient assistance programs (b) drugs we distribute to other PBMs' clients under limited distribution contracts with pharmaceutical manufacturers and (c) FreedomFP claims. 


(2) Total adjusted claims reflect home delivery claims multiplied by 3, as home delivery claims typically cover a time period 3 times longer than retail claims. 


(3) Amortization of legacy Express Scripts intangible assets include amounts in both revenues and selling, general and administrative expense. Revenue amortization is related to the customer contract with WellPoint which consummated upon closing of the NextRx acquisition in 2009.  Under U.S. GAAP standards, amortization of intangibles that arise in connection with consideration given to a customer by a vendor is characterized as a reduction of revenues.  Intangible amortization of $28.5 million ($17.6 million and $17.9 million net of tax in 2012 and 2011, respectively) is included as a reduction to revenue for the three months ended September 30, 2012 and 2011.   Intangible amortization of $85.5 million ($51.2 million and $54.0 million net of tax in 2012 and 2011, respectively) is included as a reduction to revenue for the nine months ended September 30, 2012 and 2011.  


In addition, intangible amortization of $10.1 million ($6.3 million net of tax) is included in selling, general and administrative expense in the three months ended September 30, 2012 and 2011. Intangible amortization of $30.5 million ($18.3 million and $19.3 million net of tax in 2012 and 2011, respectively) is included in selling, general and administrative expense in the nine months ended September 30, 2012 and 2011.


(4) Non-recurring transaction and integration costs include those directly related to the acquisition of Medco Health Solutions, Inc. ("Medco").   


Costs of $21.8 million ($13.5 million net of tax) and $33.7 million ($20.2 million net of tax) for the three months and nine months ended September 30, 2012, respectively, primarily composed of integration-related activities, are included in cost of revenues.


Costs of $158.9 million ($98.4 million net of tax) and $20.3 million ($12.8 million net of tax) primarily composed of severance costs, including stock compensation, are included in selling, general and administrative expense in the three months ended September 30, 2012 and 2011, respectively. Costs of $565.9 million ($339.0 million net of tax) and $20.3 million ($12.8 million net of tax) are included in selling, general and administrative expense in the nine months ended September 30, 2012 and 2011, respectively.


The Company recorded net charges of $20.2 million ($12.5 million and $12.1 million net of tax in the three months and nine months, respectively) within selling, general and administrative expenses for the three months and nine months ended September 30, 2012 in conjunction with the strategic decision to exit various businesses.


(5) Amortization of intangible assets related to the acquisition of Medco of $495.9 million ($307.0 million net of tax) and $977.8 million ($585.7 million net of tax) for the three months and nine months ended September 30, 2012, respectively is included in selling, general and administrative expense. 


(6)EBITDA is earnings before taxes, depreciation and amortization, net interest and other income (expense); or alternatively calculated as operating income plus depreciation and amortization.  EBITDA is presented because it is a widely accepted indicator of a company's ability to service indebtedness and is frequently used to evaluate a company's performance.  EBITDA, however, should not be considered as an alternative to net income, as a measure of operating performance, as an alternative to cash flow, as a measure of liquidity or as a substitute for any other measure computed in accordance with U.S. GAAP. In addition, this definition and calculation of EBITDA may not be comparable to that used by other companies.


(7)Financing costs include fees related to the amortization of remaining bridge loan fees, commitment fees related to the new credit agreement and interest and fees on the senior notes secured in conjunction with the acquisition of Medco.  Costs of $42.0 million ($26.4 million net of tax) are included interest expense in the three months ended September 30, 2011.  Costs of $85.2 million ($51.0 million net of tax) and $42.0 million ($26.5 million net of tax) are included in interest expense in the nine months ended September 30, 2012 and 2011, respectively. 


(8)Provision for income taxes includes discrete tax items of $43.5 million for the nine months ended September 30, 2012. These items primarily relate to adjustments to prior year income tax return filings and a reversal of the deferred tax asset previously established for transaction-related costs that became nondeductible upon the consummation of the Merger.  


(9) Adjusted EPS will exclude amortization of Medco-related intangible assets.  The current estimate of full year amortization based on the preliminary purchase price allocation.  The preliminary purchase price allocation may be subject to further refinement and may result in significant changes.  


(10) Adjusted EPS will exclude Medco-related transaction and integration costs. The full-year impact of these costs have yet to be determined. 

 

SOURCE Express Scripts

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. In his session at @BigDataExpo, Jack Norris, Senior Vice President, Data and Applications at MapR Technologies, reviewed best practices to ...
"Digital transformation - what we knew about it in the past has been redefined. Automation is going to play such a huge role in that because the culture, the technology, and the business operations are being shifted now," stated Brian Boeggeman, VP of Alliances & Partnerships at Ayehu, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Evatronix provides design services to companies that need to integrate the IoT technology in their products but they don't necessarily have the expertise, knowledge and design team to do so," explained Adam Morawiec, VP of Business Development at Evatronix, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.
The 22nd International Cloud Expo | 1st DXWorld Expo has announced that its Call for Papers is open. Cloud Expo | DXWorld Expo, to be held June 5-7, 2018, at the Javits Center in New York, NY, brings together Cloud Computing, Digital Transformation, Big Data, Internet of Things, DevOps, Machine Learning and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding busin...
SYS-CON Events announced today that Synametrics Technologies will exhibit at SYS-CON's 22nd International Cloud Expo®, which will take place on June 5-7, 2018, at the Javits Center in New York, NY. Synametrics Technologies is a privately held company based in Plainsboro, New Jersey that has been providing solutions for the developer community since 1997. Based on the success of its initial product offerings such as WinSQL, Xeams, SynaMan and Syncrify, Synametrics continues to create and hone inn...
Digital Transformation (DX) is not a "one-size-fits all" strategy. Each organization needs to develop its own unique, long-term DX plan. It must do so by realizing that we now live in a data-driven age, and that technologies such as Cloud Computing, Big Data, the IoT, Cognitive Computing, and Blockchain are only tools. In her general session at 21st Cloud Expo, Rebecca Wanta explained how the strategy must focus on DX and include a commitment from top management to create great IT jobs, monitor ...
Cloud Expo | DXWorld Expo have announced the conference tracks for Cloud Expo 2018. Cloud Expo will be held June 5-7, 2018, at the Javits Center in New York City, and November 6-8, 2018, at the Santa Clara Convention Center, Santa Clara, CA. Digital Transformation (DX) is a major focus with the introduction of DX Expo within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive ov...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, discussed how they built...
Recently, WebRTC has a lot of eyes from market. The use cases of WebRTC are expanding - video chat, online education, online health care etc. Not only for human-to-human communication, but also IoT use cases such as machine to human use cases can be seen recently. One of the typical use-case is remote camera monitoring. With WebRTC, people can have interoperability and flexibility for deploying monitoring service. However, the benefit of WebRTC for IoT is not only its convenience and interopera...
With tough new regulations coming to Europe on data privacy in May 2018, Calligo will explain why in reality the effect is global and transforms how you consider critical data. EU GDPR fundamentally rewrites the rules for cloud, Big Data and IoT. In his session at 21st Cloud Expo, Adam Ryan, Vice President and General Manager EMEA at Calligo, examined the regulations and provided insight on how it affects technology, challenges the established rules and will usher in new levels of diligence arou...
SYS-CON Events announced today that Evatronix will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Evatronix SA offers comprehensive solutions in the design and implementation of electronic systems, in CAD / CAM deployment, and also is a designer and manufacturer of advanced 3D scanners for professional applications.
No hype cycles or predictions of a gazillion things here. IoT is here. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, an Associate Partner of Analytics, IoT & Cybersecurity at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He also discussed the evaluation of communication standards and IoT messaging protocols, data...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, provided a fun and simple way to introduce Machine Leaning to anyone and everyone. He solved a machine learning problem and demonstrated an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intelligence and B...
Nordstrom is transforming the way that they do business and the cloud is the key to enabling speed and hyper personalized customer experiences. In his session at 21st Cloud Expo, Ken Schow, VP of Engineering at Nordstrom, discussed some of the key learnings and common pitfalls of large enterprises moving to the cloud. This includes strategies around choosing a cloud provider(s), architecture, and lessons learned. In addition, he covered some of the best practices for structured team migration an...
22nd International Cloud Expo, taking place June 5-7, 2018, at the Javits Center in New York City, NY, and co-located with the 1st DXWorld Expo will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud ...
22nd International Cloud Expo, taking place June 5-7, 2018, at the Javits Center in New York City, NY, and co-located with the 1st DXWorld Expo will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud ...